Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression

Haematologica

Volumn 90, Issue 6, 2005, Pages 810-817

  Asosingh, Kewal ^d   De Raeve, Hendrik ^b   De Ridder, Mark ^c   Storme, Guy A ^c   Willems, Angelo ^a   Van Riet, Ivan ^a   Van Camp, Benjamin ^a   Vanderkerken, Karin ^e  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d LERNER RESEARCH INSTITUTE   (United States)

^e NONE

Author keywords

Angiogenesis; CD45; Hypoxia; Myeloma

Indexed keywords

CASPASE 3; CD45 ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PIMONIDAZOLE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HYPOXIA; IMMUNOHISTOCHEMISTRY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; STATISTICAL ANALYSIS; TUMOR GROWTH;

ANIMALS; ANOXIA; ANTIGENS, CD45; APOPTOSIS; BONE MARROW CELLS; CASPASE 3; CASPASES; CELL HYPOXIA; DISEASE PROGRESSION; FLOW CYTOMETRY; HEMATOPOIESIS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; NITROIMIDAZOLES;

EID: 21244460271     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Subarsky P, Hill RP. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 2003;20:237-50.
2. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
3. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3: 721-32.
4. Pennathur-Das R, Levitt L. Augmentation of in vitro human marrow erythropoiesis under physiological oxygen tensions is mediated by monocytes and T lymphocytes. Blood 1987; 69:899-907.
5. Danet GH, Pan Y, Luongo JL, Bonnet DA, Simon MC. Expansion of human SCID-repopulating cells under hypoxic conditions. J Clin Invest 2003;112: 126-35.
6. Scortegagna M, Morris MA, Oktay Y, Bennett M, Garcia JA. The HIF family member EPAS1/HIF-2a is required for normal hematopoiesis in mice. Blood 2003;102:1634-40.
7. Guyton AC. The Book of Medical Physiology. Saunders, Philadelphia. 1991. p. 434.
8. Ceradini DJ, Kulkami AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004;10:858-64.
9. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
10. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.
11. Achilles EG, Fernandez A, Allred EN, Kisker O, Udagawa T, Beecken WD, et al. Heterogeneity of angiogenic activity in a human liposarcoma: a proposed mechanism for "no take" of human tumors in mice. J Natl Cancer Inst 2001;93:1075-81.
12. Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 1991;22:339-47.
13. Asosingh K, De Raeve H, Menu E, Van Riet I, Van Marck E, Van Camp B, et al. Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity. Blood 2004; 103:3131-7.
14. Radl J, De Glopper ED, Schuit HR, Zurcher C. Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol 1979;122:609-13.
15. Radl J, Croese JW, Zurcher C, Van den Enden-Vieveen MH, de Leeuw AM. Animal model of human disease. Multiple myeloma. Am J Pathol 1988; 132:593-7.
16. Vanderkerken K, Asosingh K, Braet F, Van Riet I, Van Camp B. Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells. Blood 1999;93:235-41.
17. + myeloma cells in the 5T2MM murine model. Cancer Res 2003;63: 3019-20.
18. Vordermark D, Brown JM. Evaluation of hypoxia-inducible factor-1alpha (HIF-1α) as an intrinsic marker of tumor hypoxia in U87 MG human glioblastoma: in vitro and xenograft studies. Int J Radiat Oncol Biol Fhys 2003;56:1184-93.
19. Durand RE, Raleigh JA. Identification of nonproliferating but viable hypoxic tumor cells in vivo. Cancer Res 1998; 58:3547-50.
20. Hypoxyprobe™-1 Data Sheet. http:/www.radonc.unc.edu/pimo/faq. htm. Accessed December 8, 2004.
21. de Ridder M, Verovski VN, Van den Berge DL, Sermeus AB, Monsaert C, Wauters N, et al. Lipid a radiosensitizes hypoxic EMT-6 tumor cells: role of the NF-κB signaling pathway. Int J Radiat Oncol Biol Phys 2003;57:779-86.
22. Bennewith KL, Raleigh JA, Durand RE. Orally administered pimonidazole to label hypoxic tumor cells. Cancer Res 2002;62:6827-30.
23. Asosingh K, De Raeve H, Van Riet I, Van Camp B, Vanderkerken K. Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis. Blood 2003;101:3136-41.
24. Giuliani N, Colla S, Morandi F, Lazzaretti M, Mancini C, Rizzoli V. Angiogenic switch in multiple myeloma patients. Blood 2003;102:1610 [abstract].
25. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Kimlinger TK, et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: Evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 2004;104:1159-65.
26. De Raeve HR, Asosingh K, Wisse E, Van Camp E, Van Marck E, Vanderkerken K. Part of the multiple myeloma associated microvessels is functionally connected to the systemic circulation: a study in the murine 5T33MM model. Virchows Archiv 2004;445:389-95.
27. +) 5T multiple myeloma cells. Exp Hematol 2001; 29:77-84.
28. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91.
29. Tuma RS. The root of tumor growth: stem cell research thrives. J Natl Cancer Inst 2004;96:502-3.
30. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414: 105-11.
31. Jones RJ, Matsui WH, Smith BD. Cancer stem cells: are we missing the target? J Natl Cancer Inst 2004;96: 583-5.
32. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004;103: 2332-6.
33. Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE, et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 2004;279:24218-25.
34. Woelfle U, Cloos J, Sauter G, Riethdorf L, Janicke F, van Diest P, et al. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 2003;63:5679-84.
35. Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M, et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 2001;193:1005-14.
36. Villars F, Bordenave L, Bareille R, Amedee J. Effect of human endothelial cells on human bone marrow stromal cell phenotype: role of VEGF? J Cell Biochem 2000;79:672-85.
37. Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon MC. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 1997; 386:403-7
38. Adelman DM, Maltepe E, Simon MC. Multilineage embryonic hematopoiesis requires hypoxic ARNT activity. Genes Dev 1999;13:2478-83.
39. Kojima H, Gu H, Nomura S, Kobata T, Carmeliet P, Semenca GL, et al. Abnormal B lymphocyte development and autoimmunity in hypoxia-inducible factor 1α-deficient chimeric mice. Proc Natl Acad Sci USA 2002; 99:2170-4.
40. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, et al. The expression and distribution of die hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000;157:411-21.
41. Wellmann S, Guschmann M, Griethe W, Erkert C, Stackelberg A, Lottaz C, et al. Activation of die HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia 2004;18: 926-23.